Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/32440
Full metadata record
DC FieldValueLanguage
dc.contributor.authorApichart Singalavanijaen_US
dc.contributor.authorKornwipa Hemaraten_US
dc.contributor.authorNapang Kedkoviden_US
dc.contributor.authorJutalai Tanterdthamen_US
dc.contributor.authorChakrapong Namatraen_US
dc.contributor.authorAdisak Trinavaraten_US
dc.contributor.authorNattawut Rodananten_US
dc.contributor.authorSomanus Thoongsuwanen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-10-19T05:29:26Z-
dc.date.available2018-10-19T05:29:26Z-
dc.date.issued2013-03-01en_US
dc.identifier.citationJournal of the Medical Association of Thailand. Vol.96, No.3 (2013), 318-323en_US
dc.identifier.issn01252208en_US
dc.identifier.other2-s2.0-84874771283en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84874771283&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/32440-
dc.description.abstractObjective: To study the prevalence of optic atrophy in patients with proliferative diabetic retinopathy (PDR) who underwent intravitreal bevacizumab injection and risk factors associated with optic atrophy. Material and Method: A retrospective case control study enrolled 269 cases (394 eyes) of patients with PDR, in which 166 cases (219 eyes) received intravitreal bevacizumab injection. Associated factors such as type of DM, hemoglobin A1c level, hypertension, hypercholesterolemia, chronic kidney disease, previous intravitreal surgery, retinal detachment, and vitreous hemorrhage were recorded. Criteria for diagnosis of optic atrophy were decreased visual acuity, pale optic disc and decreased nerve fiber layer thickness, which was measured by Stratus optical coherence tomography (OCT). The association between intravitreal bevacizumab injection and optic atrophy was analyzed by multiple logistic regression. Results: Two hundred sixty nine patients with PDR, consisting of 166 patients with intravitreal bevacizumab injection and 103 cases without bevacizumab injection. Optic atrophy was found in 11.4% (25/219 eyes) and 8% (14/175 eyes) respectively. There was no evidence that intravitreal bevacizumab injection and associated systemic diseases were related to optic atrophy. The risk factor that was related to optic atrophy was previous intravitreal surgery (adjusted odds ratio (OR), 2.57 [95% CI, 1.13, 5.84], p = 0.024). Conclusion: Anti-VEGF (bevacizumab) does not increase the risk of optic atrophy. The ophthalmologists should be aware of subsequent optic atrophy development in patients with PDR who undergo surgical intervention.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84874771283&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleOptic atrophy after anti-vascular endothelial growth factor injection in diabetic patients with proliferative diabetic retinopathyen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.